Physician

Mark T Hoffmann, MD

According to 2025 Medicare claims, Mark Hoffmann, MD (NPI: 1356342034) practices interventional cardiology in the Wausau, WI market, with the plurality of this provider's patient population coming from Marathon, WI. This provider's primary affiliated billing organization is ASPIRUS MEDICAL GROUP, INC. (NPI: 1033411822; TIN: 391670223) and primary practice location at 54401-4173. Hoffmann is affiliated with the West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Hoffmann's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,258 traditional Medicare patients, billed 2,994 HCPCS/CPT codes, and received $136,005 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 11,571 prescription claims across 1,100 beneficiaries totaling $13,866,763 in drug costs, led by Vyndamax (Tafamidis). DME data shows 307 claims. Open Payments data shows 24 records totaling $5,557. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $180,195 to $136,005. In contrast, Part D prescription costs have moved sharply higher in recent years, from $622,726 to $13,866,763. For DME billing, this smaller-volume category rose steadily, from $3,756 to $22,930.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,070	3,436	$180,195
2016	1,088	2,402	$154,749
2017	1,072	3,310	$199,834
2018	1,140	3,516	$215,650
2019	973	3,094	$179,954
2020	885	3,289	$162,256
2021	783	2,589	$135,487
2022	826	2,122	$102,969
2023	1,003	2,579	$122,376
2024	1,258	2,994	$136,005

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	570	4,959	$622,726
2016	563	5,216	$1,056,315
2017	555	4,916	$1,528,166
2018	582	4,892	$1,875,555
2019	631	5,236	$2,290,135
2020	658	5,867	$3,312,579
2021	756	6,933	$5,200,064
2022	814	8,086	$6,466,115
2023	899	9,689	$8,877,562
2024	1,100	11,571	$13,866,763

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	18	$2,602
2016	N/R	37	$876
2017	N/R	24	$842
2018	N/R	36	$1,785
2019	N/R	82	$4,174
2020	N/R	182	$196,428
2021	N/R	246	$524,169
2022	N/R	426	$1,106,512
2023	11	199	$195,259
2024	13	307	$368,417

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	253	291	$85
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	622	627	$65
94618	Test for exercise-induced lung stress	77	129	$23
36415	Insertion of needle into vein for collection of blood sample	66	171	$9
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	120	125	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	154	4,680	$3,631,231
Adempas	Riociguat	191	5,613	$2,581,494
Jardiance	Empagliflozin	1,114	61,281	$1,170,262
Opsumit	Macitentan	82	2,460	$1,038,913
Tyvaso Dpi	Treprostinil	43	1,204	$1,006,955

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J3285	Injection, treprostinil, 1 mg	N	N/R	28	$346,248
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	13	109	$12,202
K0455	Infusion pump used for uninterrupted parenteral administration of medication, (e.g., epoprostenol or treprostinol)	Y	N/R	19	$5,376
E0431	Portable gaseous oxygen system, rental; includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing	Y	N/R	91	$1,914
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	26	$1,533

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$1,557	United Therapeutics Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$4,000	CVRx, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark T. Hoffmann, MD?

Tedicare shows public-source Medicare data for Mark T. Hoffmann, MD (NPI 1356342034), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark T. Hoffmann, MD have ACO affiliation data?

Mark T. Hoffmann, MD is shown with ACO affiliation data for West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Mark T. Hoffmann, MD?

Mark T. Hoffmann, MD is linked to ASPIRUS MEDICAL GROUP, INC. (billing NPI 1033411822) in the available physician profile data.

Does Mark T. Hoffmann, MD have Open Payments data?

Mark T. Hoffmann, MD has 24 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.